Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elanco Animal Health has struggled with revenue declines and high debt load in a challenging environment. The company's leverage ratios remain high despite efforts to stabilize the business and control leverage. Elanco's guidance for 2023 was disappointing, but there have been minimal improvements in sales and earnings guidance in recent quarters.

Elanco Animal Health: Signs Of Stabilization, Amidst Still A Big Debt Pile

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has commenced a process to amend the Company's corporate governing documents as part of a comprehensive governance review following the Company's 2023 Annual Meeting of Shareholders. The Board expects to seek shareholder approval at the 2024 Annual Meeting of Shareholders for amendments to the Company's Articles of Incorporation that will: Commence a process to declassif.

Elanco Announces Corporate Governance Enhancements

GREENFIELD, Ind.--(BUSINESS WIRE)--Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced that the first shipments of Varenzin™-CA1 (molidustat oral suspension), conditionally approved by U.S. Food and Drug Administration (FDA) as the first and only treatment to control non-regenerative anemia in cats with chronic kidney disease (CKD), are shipping to veterinary clinics around the country. Anemia from CKD can dramatically affect a cat's existence, making them lethargic, reducing their.

Elanco Launches Varenzin™-CA1 (molidustat oral suspension) – the First-of-its-Kind Oral Treatment for Anemia in Cats with Chronic Kidney Disease

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 and Tuesday, September 12, 2023. Jeff Simmons, president and CEO, will participate in a fireside chat on Monday at 4:15 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco A.

Elanco to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Elanco Animal Health Incorporated (NYSE:ELAN ) Q2 2023 Earnings Conference Call August 7, 2023 8:00 AM ET Company Participants Katy Grissom - Head of Investor Relations Jeff Simmons - President and Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Mike Ryskin - Bank of America Chris Schott - JPMorgan Umer Raffat - Evercore ISI Jon Block - Stifel Nathan Rich - Goldman Sachs Brandon Vazquez - William Blair David Westenberg - Piper Sandler Operator Good morning. My name is Rob, and I will be your conference operator today.

Elanco Animal Health Incorporated (ELAN) Q2 2023 Earnings Call Transcript

The headline numbers for Elanco Animal Health Incorporated (ELAN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Elanco Animal Health Incorporated (ELAN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2023, provided guidance for the third quarter of 2023, and raised guidance for the full year 2023. “Elanco exceeded expectations for the second quarter and first half of 2023, putting us on track to return to revenue growth in the second half and raise full year guidance for revenue, adjusted EBITDA and adjusted EPS. Excluding the estimated impact of the s.

Elanco Animal Health Reports Second Quarter 2023 Results and Raises Full Year Guidance

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2022 Environmental, Social and Governance (ESG) Report highlighting enhanced governance, transparency and progress measurements. Elanco's commitment to important ESG-related topics is demonstrated across its four interconnected Healthy Purpose™ Pillars: Healthier Animals, Healthier People, Healthier Planet and Healthier Enterprise. Through numerous internal initiatives and external collaborations.

Elanco Releases 2022 Environmental, Social and Governance Report, Demonstrating Sustainability Progress in Internal Operations and Customer Collaborations

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2023 financial results on Monday, August 7, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco.

Elanco Confirms Date and Conference Call for Second Quarter 2023 Financial Results Announcement

Elanco Animal Health Incorporated (ELAN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Elanco Animal Health Incorporated (ELAN) Stock Jumps 11.7%: Will It Continue to Soar?

A top regulator confirms continued approval of an important product. The Seresto flea and tick collar has been on the market since 2013.

Why Investors Were Barking Loudly About Elanco Animal Health Stock Today

Elanco Animal Health said on Thursday the U.S. Environmental Protection Agency (EPA) has deemed the company's Seresto flea and tick collars for pets safe for use following a multi-year review.

Elanco says EPA affirms safety profile of its Seresto flea and tick collars

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) and the U. S. Environmental Protection Agency (EPA) today announced that EPA, with support from the Food and Drug Administration (FDA), has completed its comprehensive, multi-year review of the Seresto® flea and tick collar. EPA confirms continued registration of the collar. Comprehensive data affirms the safety profile of Seresto. As part of EPA's scientific review process, the agency analyzed incident data inclu.

Environmental Protection Agency (EPA) Completes Review of Seresto® Collar and Confirms Continued Registration; Data Affirms Safety Profile of the Product

Greenfield, Indiana, Fort Collins, Colorado, Basel, Switzerland and Dublin, Ireland--(Newsfile Corp. - July 4, 2023) - Elanco Animal Health Incorporated (NYSE: ELAN) ("Elanco"), a global leader in animal health, and Tonisity International Limited ("Tonisity"), an animal health and nutrition company based in Ireland, have expanded their partnership to sell Tonisity's novel, gut enhancing porcine product, Tonisity Px™, into the Philippines. Further to the joint news release dated November 15, 2022, Elanco and Tonisity entered into a distribution and promotion agreement (the "Strategic Partnership Agreement") whereby Elanco acts as the exclusive distributor of Tonisity Px in Brazil, Belgium, Denmark, France, Germany, Norway, Portugal, Spain, Sweden, and The Netherlands.

Elanco and Tonisity International Expand Strategic Partnership into The Philippines

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Jeff Simmons, President and CEO, will participate in a fireside chat on Monday, June 12 at 5:40 p.m. ET (2:40 p.m. PT). A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal Health (NYSE: E.

Elanco to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

JetBlue Airways

Petco Health and Wellness

Brookline Bancorp

Mister Car Wash

Paysafe

Select Energy Services

With the surge in artificial intelligence names and the tech industry, traders are looking for the next big thing. Sometimes, though, the best place to hunt is in companies that are currently off the radar, such as these sleeper stocks under $10.

7 Under-$10 Sleeper Stocks to Buy Before Investors Wake Up

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Stifel 2023 Jaws and Paws Conference on Thursday, June 1, 2023. Todd Young, executive vice president and CFO, will participate in a fireside chat at 1:50 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global l.

Elanco to Participate in Stifel 2023 Jaws and Paws Conference

Dublin, Ireland--(Newsfile Corp. - May 19, 2023) - Elanco Animal Health Incorporated ("Elanco"), global leader in animal health, is set to begin distributing Tonisity International Ltd.'s ("Tonisity") range of gut enhancing swine products.

Elanco to Begin Distributing Tonisity's Gut Enhancing Swine Products Following Strategic Partnership Agreement

Alibaba

Elanco Animal Health has a resilient business that raised prices without seeing a corresponding decline in volume. Alibaba should be a better stock to own this year as the Chinese economy is off to a hot start in 2023.

2 Unstoppable Growth Stocks Wall Street Thinks Can Soar by at Least 70%

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.36 per share a year ago.

Elanco Animal Health Incorporated (ELAN) Q1 Earnings and Revenues Beat Estimates

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2023, provided guidance for the second quarter of 2023, and raised the bottom-end of guidance for the full year 2023. “Elanco delivered sequentially improved underlying business performance in the first quarter driven by recovering business conditions and actions we have taken to strengthen our commercial positioning, notably in U.S. Pet Health driven by im.

Elanco Animal Health Reports First Quarter 2023 Results

Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Elanco Animal Health Incorporated (ELAN) is Poised to Beat Earnings Estimates Again

Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has provided a conditional license for the first Canine Parvovirus Monoclonal Antibody. This is the first and only approved therapeutic solution proven to treat canine parvovirus — one of the most contagious and deadly viruses a dog can contract with a 91% mortality rate if not treated with supportive carei. The treatment is the first monoclonal antibody fo.

Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus

Athian's livestock carbon credit marketplace completes latest round of funding thanks to the investment by California Dairies, Inc. and DSM Venturing INDIANAPOLIS , May 1, 2023 /PRNewswire/ -- Athian (athian.ai) announces the completion of their seed funding round with investments from two strategic partners: DSM Venturing, the corporate venture arm of Royal DSM, a global, purpose-led company in Health, Nutrition & Bioscience, and California Dairies, Inc. (CDI), the largest dairy farmer-owned cooperative in California and second largest in the United States. Athian, the world's first carbon marketplace for the livestock sector, advances the global acceptance of its novel transactional carbon credit inset program with this investment from DSM Venturing and CDI, along with previous investors, Elanco Animal Health Incorporated (NYSE: ELAN), Tyson Ventures and Newtrient LLC.

News for Elanco Animal Health Inc Stock (ELAN)